-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Zhitong Finance App, Cinda Biotech (01801.HK) announced that its partner Ollin Biosciences, Inc. (Ollin) has reached an acquisition agreement with Johnson & Johnson (NYSE: JNJ). The Ollin core pipeline OLN324 (Cinda Biotech R&D code: IBI324) was developed by Cinda Biotech and authorized to the outside world.
Share
Listen to the news
According to Zhitong Finance App, Cinda Biotech (01801.HK) announced that its partner Ollin Biosciences, Inc. (Ollin) has reached an acquisition agreement with Johnson & Johnson (NYSE: JNJ). The Ollin core pipeline OLN324 (Cinda Biotech R&D code: IBI324) was developed by Cinda Biotech and authorized externally.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending